Posts

Alopecia Clinical Trials Review

Alopecia Market Size

/in /by

Alopecia Market Size

The global alopecia market size is expected to reach USD 14.2 billion by 2028. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The strong presence of pipeline products and increasing approval for laser-based therapy to treat hair loss conditions are major factors anticipated to drive growth.

Moreover, rising awareness among patients about alopecia and its treatments, increasing government initiatives, supportive regulations & laws, and improvements in healthcare infrastructure are factors expected to propel market growth over the forecast period.

Technological advancements in alopecia treatment are among the key drivers of this market. There are two FDA-approved therapeutics for alopecia-Rogaine and Propecia. There has been an increase in market penetration of generics after patent expiries of both drugs. However, the launch of several promising pipeline candidates over the forecast years such as Xeljanz (tofacitinib), Breezula (clascoterone), Jakafi (ruxolitinib), SM04554, and Lumigan (Bimatoprost) is expected to substantially drive the growth of the market in the near future.

The introduction of low-level laser therapy that helps stimulate hair growth is expected to increase the treatment rate among patients facing hair loss. In addition, the launch of laser caps, helmets, combs, and bands is also anticipated to boost the market growth. For instance, Capillus Laser Cap, iGrow Laser Helmet, iRestore Hair Growth System, and Hairmax Laser devices are some of the technologically advanced products available in the market.

Moreover, the increasing prevalence of diseases such as cancer, Polycystic Ovary Syndrome, and rheumatoid arthritis which are associated with hair loss is also expected to boost the treatment rate of hair loss in the near future. For instance, as per the U.S. Department of Health and Human Services, nearly 5 million women in the U.S. are affected by PCOS. Furthermore, according to the GBD database, the prevalence of PCOS in European countries, such as France, increased from 872,351 to 882,322 in 2018 & 2019, respectively, and in the U.K., the prevalence was found to be 1,134,082 to 1,142,498.

Market players are increasingly forming partnerships and licensing agreements to enhance their product capabilities and promote the outreach of their products. For instance, the iGrow laser system has a partnership with China Central Pharmaceuticals in China. China Central Pharmaceuticals holds exclusive distribution rights over Aspira in the country.

Moreover, Capillus, LLC has collaborated with Svenson, a hair loss treatment clinic to expand the distribution of laser therapy caps in Europe and the Asia Pacific region. The partnership with local players and service providers is expected to increase the adoption of innovative therapy for hair loss treatment.

Additionally, companies are actively participating in scientific conferences and conducting awareness campaigns for creating brand awareness. For instance, in February 2021, Hairmax welcomed Mary Brunetti as the brand ambassador to increase brand awareness about dealing with COVID-19-induced hair loss, as well as hereditary loss. Moreover, it plans to leverage the popularity of the brand ambassador to showcase its target market as to how its products can help regrow and revitalize their hair.

However, reimbursement remains one of the major challenges in this market. Since most of the treatment modalities are considered as not medically essential and are categorized as cosmetic procedures, the treatment for hair loss is generally not covered under insurance plans. Out-of-pocket expenses for alopecia treatment usually include prescription drug copays, frequent doctor visits, and co-insurance for procedures.

Moreover, increasing adoption of substitutes, such as traditional medicines-Ayurvedic, Chinese, and herbal medications may hamper the growth of the market. Based on results from the GlaxoSmithKline plc sponsored survey, around 22.7% of the patients took Chinese medications for treating male androgenetic alopecia in South Korea followed by Taiwan with 22.0% patients.

Alopecia Market Report Highlights

  • In 2020, the alopecia areata segment accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Key late-stage pipeline candidates in the treatment of hair loss include: Xeljanz (tofacitinib), Breezula (clascoterone), and SM04554 are expected to fuel the growth in the coming years
  • Alopecia universalis is anticipated to witness the fastest growth during the forecast period owing to the potential pipeline products, such as BNZ-1 (Bioniz Therapeutics), and stem cell educator therapy with minoxidil (Tianhe Stem Cell Biotechnologies, Inc.)
  • North America was the largest market in 2020 mainly due to a high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improved healthcare infrastructure
  • Europe held the second-largest market share in 2020 given the high prevalence of AGA i.e., 80% and 50% in both the men and women of the region, respectively

Alopecia Market Size

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Market Size

/in /by

Alopecia Market Size

The global alopecia market size is expected to reach USD 14.2 billion by 2028. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The strong presence of pipeline products and increasing approval for laser-based therapy to treat hair loss conditions are major factors anticipated to drive growth.

Moreover, rising awareness among patients about alopecia and its treatments, increasing government initiatives, supportive regulations & laws, and improvements in healthcare infrastructure are factors expected to propel market growth over the forecast period.

Technological advancements in alopecia treatment are among the key drivers of this market. There are two FDA-approved therapeutics for alopecia-Rogaine and Propecia. There has been an increase in market penetration of generics after patent expiries of both drugs. However, the launch of several promising pipeline candidates over the forecast years such as Xeljanz (tofacitinib), Breezula (clascoterone), Jakafi (ruxolitinib), SM04554, and Lumigan (Bimatoprost) is expected to substantially drive the growth of the market in the near future.

The introduction of low-level laser therapy that helps stimulate hair growth is expected to increase the treatment rate among patients facing hair loss. In addition, the launch of laser caps, helmets, combs, and bands is also anticipated to boost the market growth. For instance, Capillus Laser Cap, iGrow Laser Helmet, iRestore Hair Growth System, and Hairmax Laser devices are some of the technologically advanced products available in the market.

Moreover, the increasing prevalence of diseases such as cancer, Polycystic Ovary Syndrome, and rheumatoid arthritis which are associated with hair loss is also expected to boost the treatment rate of hair loss in the near future. For instance, as per the U.S. Department of Health and Human Services, nearly 5 million women in the U.S. are affected by PCOS. Furthermore, according to the GBD database, the prevalence of PCOS in European countries, such as France, increased from 872,351 to 882,322 in 2018 & 2019, respectively, and in the U.K., the prevalence was found to be 1,134,082 to 1,142,498.

Market players are increasingly forming partnerships and licensing agreements to enhance their product capabilities and promote the outreach of their products. For instance, the iGrow laser system has a partnership with China Central Pharmaceuticals in China. China Central Pharmaceuticals holds exclusive distribution rights over Aspira in the country.

Moreover, Capillus, LLC has collaborated with Svenson, a hair loss treatment clinic to expand the distribution of laser therapy caps in Europe and the Asia Pacific region. The partnership with local players and service providers is expected to increase the adoption of innovative therapy for hair loss treatment.

Additionally, companies are actively participating in scientific conferences and conducting awareness campaigns for creating brand awareness. For instance, in February 2021, Hairmax welcomed Mary Brunetti as the brand ambassador to increase brand awareness about dealing with COVID-19-induced hair loss, as well as hereditary loss. Moreover, it plans to leverage the popularity of the brand ambassador to showcase its target market as to how its products can help regrow and revitalize their hair.

However, reimbursement remains one of the major challenges in this market. Since most of the treatment modalities are considered as not medically essential and are categorized as cosmetic procedures, the treatment for hair loss is generally not covered under insurance plans. Out-of-pocket expenses for alopecia treatment usually include prescription drug copays, frequent doctor visits, and co-insurance for procedures.

Moreover, increasing adoption of substitutes, such as traditional medicines-Ayurvedic, Chinese, and herbal medications may hamper the growth of the market. Based on results from the GlaxoSmithKline plc sponsored survey, around 22.7% of the patients took Chinese medications for treating male androgenetic alopecia in South Korea followed by Taiwan with 22.0% patients.

Alopecia Market Report Highlights

  • In 2020, the alopecia areata segment accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Key late-stage pipeline candidates in the treatment of hair loss include: Xeljanz (tofacitinib), Breezula (clascoterone), and SM04554 are expected to fuel the growth in the coming years
  • Alopecia universalis is anticipated to witness the fastest growth during the forecast period owing to the potential pipeline products, such as BNZ-1 (Bioniz Therapeutics), and stem cell educator therapy with minoxidil (Tianhe Stem Cell Biotechnologies, Inc.)
  • North America was the largest market in 2020 mainly due to a high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improved healthcare infrastructure
  • Europe held the second-largest market share in 2020 given the high prevalence of AGA i.e., 80% and 50% in both the men and women of the region, respectively

Alopecia Market Size

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Treatment Market Investigation

/in /by

Alopecia Treatment Market Investigation Highlighting Grow

The Alopecia Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.

Alopecia is a condition associated with excessive hair loss or hair damage. Treatment of alopecia plays a key role in modern healthcare, since it aids hair fall prevention and hair regrowth. Unhealthy lifestyle, hormonal imbalance and ageing, are certain the factors causing condition of alopecia.

The global alopecia treatment market size accounted for US$ 7,325.0 million in 2017 and is projected to witness a 4.9% CAGR over the forecast period (2018–2026).

Rising product approvals and launches, along with robust pipelines are expected to drive the global market growth

Rising launches of products along with robust pipelines are expected to propel the global alopecia treatment market over the forecast period. For instance, Fidia Pharma, in November 2018, launched in Italy, Trinov hair growth lotion for growth of hair. Furthermore, Eli Lilly and Company, in September 2018, began clinical trial of phase 2 to assess efficacy and the safety of the drug Baricitinib to treat alopecia areata patients. This study is projected to be over by August 2022.

Increasing initiatives including crowdfunding campaigns along with rising collaborations by market companies is expected to boost the growth of the global alopecia treatment market over the forecast period. For instance, the U.K.-based firm developing restoration therapies cellular hair-HairClone, in 2018, launched its campaign for public crowdfunding, in collaboration with Capital Cell, a company of crowdfunding. Similarly, RepliCel Life Sciences Inc. and Shiseido Company, Limited, in May 2013, declared technology development transfer framework agreement and collaboration for RepliCel’s technology of hair regeneration – RCH-01.

Increasing Alopecia Areata’ prevalence and high focus on development research within North America are expected to boost the growth of the market.

North America region holds the largest share in the global alopecia treatment market, due to rising prevalence of Alopecia Areata and activities of research by market companies. For instance, in 2017, as per the National Alopecia Areata Foundation (NAAF), alopecia areata troubles over 6.8 Mn individuals in the U.S. with 2.1% lifetime risk. Furthermore, the NAAF is focusing on broadening efforts of research through 2 committees, such as the Clinical Research Advisory Council (CRAC) and the Basic Research Advisory Council (BRAC), to develop the Alopecia Areata Treatment Development Program

Rising strategies of acquisition in this region by market companies are key factors expected to drive the growth of the global alopecia treatment market. For instance, Aclaris Therapeutics, Inc., in August 2017, acquired Confluence Life Sciences, Inc. that expanded the immunology and inflammation pipeline of Aclaris with the inclusion of the lead product candidate of Confluence, CDD-450, IL2-inducible T-cell kinase inhibitor, and topical Janus kinase inhibitors.

Furthermore, market players collaborating with regulation authorities along with other governmental organizations is expected to further drive the global North America alopecia treatment market growth during the forecast period. For instance Helomics, Precision Therapeutics Inc., and the National Alopecia Areata Foundation (NAAF), in April, 2019, entered in an agreement for treating people suffering from autoimmune skin disease known as alopecia areata. This agreement was aimed at providing a next-generation patient registry for driving research on novel treatments to people having this disease.

Major Key Players Include In Alopecia Treatment Market: Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

Main points in Alopecia Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Alopecia Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Alopecia Treatment Industry Impact

Chapter 2 Global Alopecia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Alopecia Treatment (Volume and Value) by Type
2.3 Global Alopecia Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Alopecia Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Alopecia Treatment Market Analysis
Chapter 6 East Asia Alopecia Treatment Market Analysis
Chapter 7 Europe Alopecia Treatment Market Analysis
Chapter 8 South Asia Alopecia Treatment Market Analysis
Chapter 9 Southeast Asia Alopecia Treatment Market Analysis
Chapter 10 Middle East Alopecia Treatment Market Analysis
Chapter 11 Africa Alopecia Treatment Market Analysis
Chapter 12 Oceania Alopecia Treatment Market Analysis
Chapter 13 South America Alopecia Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Alopecia Treatment Business
Chapter 15 Global Alopecia Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions

Alopecia Treatment Market Investigation Highlighting Grow

Source

Recent Posts

Trial of Ritlecitinib in Alopecia Areata

Trial of Ritlecitinib in Alopecia Areata

/in /by

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2

Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 per cent scalp hair loss after six months of treatment versus placebo.

European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 per cent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.

A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 per cent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo.

This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups.

The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles).

There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

Full results from this study will be submitted for future scientific publication and presentation. These data, together with data that will become available from ALLEGRO-LT, will form the basis for planned future regulatory filings.

Ritlecitinib is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In laboratory studies, ritlecitinib has been shown to block the activity of signalling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata.3

Ritlecitinib, which was granted Breakthrough Therapy designation from the U.S. FDA for the treatment of alopecia areata in September 2018, is also being evaluated for vitiligo, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

About the Phase 2b/3 ALLEGRO Trial

This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718). Patients included in the study had 50 per cent or more hair loss of the scalp, including patients with alopecia totalis (complete scalp hair loss) and Alopecia Universalis (complete scalp, face and body hair loss), and were experiencing a current episode of alopecia areata that had lasted between six months and ten years. Patients were randomized to receive ritlecitinib 50 mg or 30 mg (with or without one month of initial treatment with once-daily ritlecitinib 200 mg), ritlecitinib 10 mg or placebo.

The primary endpoint was the proportion of patients with scalp hair regrowth in response to ritlecitinib treatment, based on an absolute SALT Score ≤20 at Week 24. SALT is a tool that measures the amount of scalp hair loss. The tool divides the scalp into standard regions, and each region contributes to the total SALT score, which ranges from 0 to 100. A SALT score of 0 corresponds to no scalp hair loss, while a SALT score of 100 corresponds to a total lack of hair on the scalp.4

More information about the Phase 2b/3 ALLEGRO trial can be found at https://www.clinicaltrials.gov under the identifier NCT03732807.

About Alopecia Areata

Alopecia areata is an autoimmune disease characterized by patchy hair loss, almost always involving the scalp, but sometimes also involving the face (eyebrows, eyelashes, beard), the whole scalp or the whole body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out.1,2 The mean age of onset is between 25 and 35 years, but it can also impact older adults, children and adolescents, and is seen in both sexes and all ethnicities.1,2 Alopecia areata is associated with poor health-related quality of life for many patients, who may suffer from serious psychological consequences, including depression and anxiety.1

1 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology. 2015;8:397-403. doi:10.2147/CCID.S53985.

2 Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature reviews Disease primers. 2017;3:17011. doi:10.1038/nrdp.2017.11.

3 King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20:S0190-9622(21)00601-0. doi: 10.1016/j.jaad.2021.03.050.

4 Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

/in /by

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market

/in /by

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Androgenic Alopecia Drug Market Size and Forecasts 2021 to 2027

The Global Androgenic Alopecia Drug Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.

Global Androgenic Alopecia Drug Market Size, Trends, Growth, Competitive Landscape and Key Regional Analysis to 2027” offers broad information and understanding of the Androgenic Alopecia Drug markets. The report analyses the Androgenic Alopecia Drug market for the historical (2016–2020) and forecast (2021–2027) periods. The report includes drivers, restraints and opportunities influencing the market, market size analysis with respect to revenue.

The report also provides a snapshot of the competitive landscape of the key players operating in the market along with the percentage market share of the top players. The report has a section on the impact of COVID-19 on the Androgenic Alopecia Drug market at the global and country levels.

This analysis includes demand & supply-side implications of the Androgenic Alopecia Drug market in 2019. The report is built using data and information sourced from primary & secondary research, proprietary databases paid database among others.

Androgenic Alopecia Drug Market Snapshot

Scope of the Androgenic Alopecia Drug Market Report:

This report provides an in-depth analysis of the Global Androgenic Alopecia Drug Market. The market estimates and forecasts provided in the research report are the results of in-depth secondary research coupled with primary interviews and in-house expert opinions. These market estimates and forecasts have been considered by reviewing the impact of various political, social, and economic factors along with the current market scenarios affecting the Androgenic Alopecia Drug market growth

Along with the Androgenic Alopecia Drug market summary, which includes the market dynamics comprising of drivers, restraints, and opportunities the chapter also includes a Porter’s Five Forces analysis which explains: the threat of new entrants, buyers bargaining power, bargaining power of supplier, the threat of substitutes, and competitive rivalry in the Global Androgenic Alopecia Drug Market. Furthermore, the supply chain analysis explains the various participants, such as raw material suppliers, system integrators, distributors, intermediaries and end-users within the ecosystem of the Androgenic Alopecia Drug market. It provides vendor landscape at the global level and summary of the key upcoming projects/ products

Segments Covered in the Androgenic Alopecia Drug Market Report:

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2016 to 2027.

Global Androgenic Alopecia Drug Market, By Product

  • RK-023
  • Refagro
  • RCH-01
  • SM-04554
  • HYG-440
  • Others

Global Androgenic Alopecia Drug Market, By Application

  • Clinic
  • Hospital
  • Home Use

Androgenic Alopecia Drug Market Regional Overview:

The report offers in-depth analysis of the Androgenic Alopecia Drug market at the global, regional (North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa) and key country (the US, Canada, China, India, Japan, South Korea, the U.K., Germany, France, Brazil, Mexico) levels. The market estimates and forecasts for the segmentation mentioned in the study will be provided at regional and country level. The market estimates and forecast will help understand the dominant region in 2020 and will further enlighten the upcoming region that will generate major revenue in the Androgenic Alopecia Drug market.

Global Androgenic Alopecia Drug Market: Competitive Landscape

The market analysis includes a chapter solely dedicated for key players operating in the Global Androgenic Alopecia Drug Market wherein the analysis provide an insight of the business overview, financial statements, product overview, and the strategic initiatives adopted by the market players. The companies mentioned in the study can be customized according to the client’s requirements.

Global Androgenic Alopecia Drug Market, Key Players

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

Key Questions Addressed:

  • Which innovative technology trends are expected over the next seven years?
  • Which sub segment is likely to get the maximum opportunity to grow during the forecast period?
  • Which region is projected to lead with the highest market share by 2027?
  • How are companies instigating organic and inorganic strategies to gain a surge in the market share?

Global Androgenic Alopecia Drug Market: Research Methodology

The research methodology is a mix of primary research, secondary research and industry opinion leaders. Moreover, secondary research comprises of sources such as company annual reports, press releases, and research papers related to the industry. Other sources include government websites, trade journals and associations are also been reviewed for developing business growth strategies in Androgenic Alopecia Drug Market.

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Source

Recent Posts

Alopecia Areata- Market Insight

Alopecia Areata- Market Insight

/in /by

Alopecia Areata- Market Insight, Epidemiology and Market Forecast -2030

Alopecia Areata Market

DelveInsight’s “Alopecia Areata – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alopecia Areata market report provides current treatment practices, emerging drugs, Alopecia Areata market share of the individual therapies, current and forecasted Alopecia Areata market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alopecia Areata treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Alopecia Areata Disease Understanding and Treatment Algorithm

The DelveInsight Alopecia Areata market report gives a thorough understanding of the Alopecia Areata by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Alopecia Areata.

Treatment

It covers the details of conventional and current medical therapies available in the Alopecia Areata market for the treatment of the condition. It also provides Alopecia Areata treatment algorithms and guidelines in the United States, Europe, and Japan.

Alopecia Areata Epidemiology 

The Alopecia Areata epidemiology division provides insights about historical and current Alopecia Areata patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted Alopecia Areata epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Alopecia Areata Epidemiology

The epidemiology segment also provides the Alopecia Areata epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Alopecia Areata Drug Chapters

The drug chapter segment of the Alopecia Areata report encloses the detailed analysis of Alopecia Areata marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Alopecia Areata clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Alopecia Areata treatment.

Alopecia Areata Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Alopecia Areata treatment.

Alopecia Areata Market Outlook

The Alopecia Areata market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Alopecia Areata market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alopecia Areata market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Alopecia Areata market in 7MM.

The United States Market Outlook

This section provides the total Alopecia Areata market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Alopecia Areata market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Alopecia Areata market size and market size by therapies in Japan is also mentioned.

Alopecia Areata Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched in the market during the study period 2017-2030. The analysis covers Alopecia Areata market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alopecia Areata Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alopecia Areata key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Alopecia Areata emerging therapies.

Reimbursement Scenario in Alopecia Areata

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Alopecia Areata domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Alopecia Areata market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Alopecia Areata Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Alopecia Areata, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Alopecia Areata epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Alopecia Areata is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Alopecia Areata market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alopecia Areata market

Report Highlights

  • In the coming years, the Alopecia Areata market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Alopecia Areata R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Alopecia Areata. The launch of emerging therapies will significantly impact the Alopecia Areata market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Alopecia Areata
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Alopecia Areata Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Alopecia Areata Pipeline Analysis
  • Alopecia Areata Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alopecia Areata Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Alopecia Areata Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Alopecia Areata Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Alopecia Areata market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Alopecia Areata total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Alopecia Areata market size during the forecast period (2017-2030)?
  • At what CAGR, the Alopecia Areata market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Alopecia Areata market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Alopecia Areata market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Alopecia Areata?
  • What is the historical Alopecia Areata patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Alopecia Areata in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alopecia Areata?
  • Out of all 7MM countries, which country would have the highest prevalent population of Alopecia Areata during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Alopecia Areata treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Alopecia Areata in the USA, Europe, and Japan?
  • What are the Alopecia Areata marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Alopecia Areata?
  • How many therapies are developed by each company for Alopecia Areata treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Alopecia Areata treatment?
  • What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Alopecia Areata therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Alopecia Areata and their status?
  • What are the key designations that have been granted for the emerging therapies for Alopecia Areata?
  • What are the global historical and forecasted market of Alopecia Areata?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Alopecia Areata market
  • To understand the future market competition in the Alopecia Areata market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Alopecia Areata in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Alopecia Areata market
  • To understand the future market competition in the Alopecia Areata market

Alopecia Areata- Market Insight, Epidemiology and Market Forecast -2030

Source

Recent Posts

Alopecia Treatment Market Size

Alopecia Treatment Market Size

/in /by

Alopecia Treatment Market Size

Detailed study and analysis of the Global Alopecia Treatment Market highlights new trends in the Alopecia Treatment industry and provides companies with trading insights.

This study helps manufacturers, suppliers and investors, CEOs to identify opportunities and business optimization strategies to improve their value in the global Alopecia Treatment market. Provides important information for well-known companies that are one of the top-performing companies. The report provides comprehensive coverage of existing and potential markets as well as an assessment of competitiveness in changing market scenarios.

The latest Alopecia Treatment market research report entails a detailed examination of important aspects such as the scope, global demand, attractiveness, profitability, and potential of this vertical over 2020-2026. Moreover, it lays strong emphasis on the various sub-markets and uncovers the major growth avenues, followed by an in-depth examination of the competitive landscape.

As stated by the experts, the industry is anticipated to amass notable returns throughout the forecast period, registering XX% CAGR throughout.

The research literature also highlights the impact of Covid-19 and recommends multiple solutions for effectively handling the market turbulence. Apart from this, it also covers the recent acquisitions, partnerships, mergers, and other growth strategies of the leading players to help stakeholders in effortless decision-making.

Key features of the Alopecia Treatment market report:

  • Impact of the Covid-19 pandemic on the industry progression
  • Records of the total sales, total returns, and market shares
  • Key industry trends
  • Rewarding prospects
  • Growth rate approximations for the market
  • Advantages and disadvantages of using direct and indirect sales channels
  • Prominent distributors, dealers, and traders

Alopecia Treatment market segments covered in the report:

Geographical fragmentation: North America, Europe, Asia-Pacific, South America, Middle East & Africa

  • Market examination at country and regional level
  • Sales amassed, returns gathered, and industry shares acquired by each regional contributor
  • Estimations for the revenue and growth rate of each regional market over the forecast duration

Product types:

  • Topical Drugs
  • Oral Drugs
  • Injectable
  • Hair Transplant Services and Other
  • Pricing patterns for each product type
  • Market share evaluation on the basis of sales and returns garnered by each product segment

Application spectrum:

  • Hospitals
  • Dermatology And Trichology Clinics
  • Home Care Settings and Other
  • Product pricing considering the application reach
  • Revenue and sales accrued by each application category over the analysis period

Competitive dashboard:

  • The major players covered in Alopecia Treatment are:
  • Teva Pharmaceutical Industries
  • Taisho Pharmaceutical Holdings
  • Reddy’s Laboratories
  • Merck
  • Himalaya Drug
  • Johnsoni 1/4 ?Johnson
  • Cellmid andCipla
  • Business synopsis of the listed companies
  • Product and service range of the leading players
  • Accounts of the sales, pricing models, revenue, gross margin, and market share of each company
  • SWOT studies of the major companies
  • Evaluation of the industry’s concentration ratio and rate of commercialization
  • Assessment of the business strategies implemented by the leading companies

The Study Objectives are:

  • To analyze and research the global Alopecia Treatment status and future forecast involving production, revenue, consumption, historical data and forecast.
  • To present the key Alopecia Treatment manufacturers, production, revenue, market share, and recent development.
  • To split the breakdown data by regions, type, manufacturers and applications.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends, drivers, influence factors in global and regions.
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy:

  • Understand the demand for Alopecia Treatment to determine the viability of the market.
  • Identify the developed and emerging markets where Alopecia Treatment are offered.
  • Identify the challenge areas and address them.
  • Develop strategies based on the drivers, trends and highlights for each of the segments.
  • Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
  • Recognize the key competitors of this market and respond accordingly.
  • Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
  • Define the competitive positioning by comparing the products and services with the key players in the market.

Alopecia Treatment Market Size

Source

Recent Posts

Stem Cell Alopecia Treatment Market

Stem Cell Alopecia Treatment

/in /by

U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market

This insightful report has a lot to give on U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market covering wide geographic scope around the world.

The U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. The report is focused on gaining various market trends, dynamics, growth drivers, Strengths, weaknesses, opportunities, Threats restraining the market growth.

Further, the report offers detailed visions into various growth opportunities and challenges based on various types of products, applications, end-users and countries, among others.

The Key players operating in the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market are:

Orange County Hair Restoration Centre
Hair Sciences Centre of Colorado
Anderson Centre for Hair
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Centre, PLC
NovaGenix
Virginia Surgical Centre
Hair Transplant Institute of Miami
Colorado Surgical Centre & Hair Institute
Tampa Bay Hair Restoration

Report Scope:

This report gives a complete view of the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market providing knowledgeable insights to the users. The report is verified and compiled by industry experts focusing on the key information that are required by the users or clients.

The Researchers have studied Marketing, government initiatives, political environment, and social scenarios that are likely to contribute to the growth of the regional markets. Analysis of various regional market trends, qualitative and quantitative data corresponding the market size for the years 2018 and 2019, estimates for 2020, and growth forecast for the period from 2021 to 2027.

Attractive investment propositions in the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market based on various segments such as product type, application, end-user etc. Key driving and success factors along with agony points in the form of growth drivers and restraints governing the market outlook along with future trend analysis.

Comprehensive company profiles giving visions into their supply chain analysis, Financial strategies, revenue information, product offerings, Market and Sales strategies and recent market activities.

Information on industry value chain analysis of the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market providing an investigative study of key stakeholders involved, which could expedite market participants in formulating appropriate strategies.

The competitive view of the xxx and market share analysis based on the company’s performance and customer reach. Insights on Competition, Customer and Market for making informed decisions.

Report Overview:

This project study is conducted with a global point of view in terms of the various segments in the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market. Market sizing and forecast have been conducted for 5 geographic regions viz. Europe, Middle East and Africa (MEA), North America, Latin America and Asia-Pacific along with the below-mentioned list of countries present in it. Market sizing data is covered in US$ with historic data for the years 2018 and 2019, 2020 as the base year along with estimations and forecast for the period from 2021 to 2028.

The ongoing COVID-19 pandemic has had a significant impact on overall international trade and businesses. This report provides the latest insights into the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market factoring in various effects of the industry disruptions and halts caused by COVID-19.

Market Segmentation:

U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market, by Type:
Type 1
Type 2
Other Types

U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market, by Application:

Application 1
Application 2
Other Applications

U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market, by Geography:

North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Korea
SEA countries
Rest of Asia Pacific
Latin America
Brazil
Argentina
Peru
Rest of Latin America
Middle East and Africa (MEA)
GCC Countries
South Africa
UAE
Saudi Arabia
Rest of MEA

FAQs –

How big is the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market?
What is the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market growth?
Which are the regions for investments?
What is the COVID 19 analysis of U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market?
Which are the preferred low-cost/best cost sourcing countries?
Which are the key suppliers for the U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market?

U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market

Source

Recent Posts

Alopecia Market Size And Forecast

Alopecia Market Size And Forecast

/in /by

Alopecia Market Size And Forecast

Alopecia Market was valued at USD 2.68 Billion in 2020 and is projected to reach USD 4.89 Billion by 2028, growing at a CAGR of 7.9% from 2021 to 2028.

Changing lifestyle ad rising prevalence of androgenic and areata alopecia across the globe is primary factors for driving growth of Global Alopecia Market. Also, the rise in disposable income of the people and growing awareness regarding alopecia treatment is fueling the growth of Global Alopecia Market. The Global Alopecia Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Alopecia Market Definition

Alopecia areata is also called as spot baldness. It is a medical condition in which hair is lost from some or all areas of the body. Often it results in few bald spots on the scalp of the people. Generally size of spot is of coin. In few cases all the hair on the scalp or the body may lose for permanent.

Alopecia areata can be considered as an autoimmune disorder resulting from a breach in the immune privilege of the hair follicles. Risk factor for alopecia areata includes family history of the same medical condition. The mechanism involves failure by the body to recognize its own cells due to destruction of the hair follicle.

Till now there is no cure for the condition but some medications are tried for regrowth such as cortisone injection, sunscreen to protect the area being affected from cold and sun, glass if incase eyelashes has affected or missing. Another type alopecia andrgenetic which is common in the gender, in men such condition is also recognized as male-pattern baldness.

In this case hair is lost in well-defined manner. After some time hairline foam characteristic ‘M’ which is often progressing to the partial or complete baldness.in case of female it is different condition then male. In women, hair becomes thinner than normal from all over the head and often it further leads to total baldness. Androgenetic alopecia in men’s is resulted from some medical conditions such as coronary heart disease, enlargement of prostate, hypertension and many others.

Global Alopecia Market Overview

Changing lifestyle such as immoderate intake of alcohol and tobacco, and growing stress indices among the people are considered as major factor for rising prevalence of alopecia. Though the epidemiology of the disease is unknown, the genetic factor is considered as a one of the cause and linked to several cases of alopecia. In addition, rise in disposal income of the people and building emphasis on aesthetics are poised to drive the market growth of alopecia product.

Furthermore, aging and anomalies also boosting demand for alopecia treatment. Ender also plays important role in disease susceptibility. As per American Hair Loss Association, around 95% of the hair loss in men is due to androgenic alopecia and awareness among consumers is fueling the growth of Global Alopecia Market.

Moreover, rising prevalence of chronic disorders such as Polycystic Ovary Disease (PCOD), hyperthyroidism, acute stress disorder, hypothyroidism, cancer, lupus, and hypopituitarism are influencing the Global Alopecia Market.

New drug and technologies developments in the field such as emergence of rapid-action JAK inhibitors and hair growth stimulation through PRP treatment and pluripotent stem cells are accelerating the growth of Global Alopecia Market. However, high cost of treatment and lack of awareness in underdeveloped countries are anticipated to restrict the growth of Global Alopecia Market. Nevertheless, launch of new products and technologies are expected to generate new opportunities for the Global Alopecia Market during forecasted period.

Global Alopecia Market Segmentation Analysis

Global Alopecia Market is segmented based on Disease Type, Sales Channel, Gender, End-User, And Geography.

Alopecia Market, By Disease Type

• Alopecia areata
• Androgenetic alopecia
• Others

Based on Disease Type, Alopecia Market is segmented as Alopecia areata, Androgenetic alopecia and others. Alopecia areata sement is expected to hold largest share in the Alopecia Market. The growth is contributed to the high disease prevalence across the globe and increasing consumer awareness regarding treatments. Also, alopecia is most prevalent in the people who are suffering from autoimmune disorders. Androgenetic alopecia segment is expected to grow at fastest pace due to launch of multiple promising pipeline candidates and significant growth in the incidence rate.

Alopecia Market, By Sales Channel

• OTC
• Prescriptions

Based on Sales Channel, Alopecia Market is bifurcated into OTC and Prescriptions. Among these two segments, Prescriptions segment is expected to hold largest share in the alopecia market by sales channels. Various factors that are driving the growth of segments are cost effective treatment, easy accessibility of therapies and increasing number of approvals for medications.

Alopecia Market, By Gender

• Male
• Female

Based on Gender, Alopecia Market is bifurcated into Male and Female. Among these two segments, male segment are dominating the Alopecia Market, By Gender as androgen is leading cause of androgenic alopecia in men also, and increasing geriatric population across the globe and increasing tobacco intake by people are fueling the growth of male segment.

Alopecia Market, By End-User

• Homecare setting
• Dermatology clinics

Based on End-User, Alopecia Market is bifurcated into Homecare setting and Dermatology clinics. Among these two, Dermatology clinics segment is dominating the market. The growth is attributed to the increasing number of hair transplantation, and restoration surgeries. Homecare settings segment is also growing due to broadening penetration of laser treatment and rise in regulatory sanctions of homecare products.

Alopecia Market, By Geography
  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

On the basis of Geography, the Global Alopecia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is expected to hold largest market share due to growing advancement in the technology, novel product development and increasing disposal income of the people in the region is fueling the growth of alopecia market in the region. Asia-Pacific is expected to grow at fastest pace over the next few years. Large population base and growing consumer awareness regarding treatments are expected to boost the growth of alopecia market in the region.

Key Players in Alopecia Market

The “Global Alopecia Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Cipla Inc., Johnson and Johnson AG, Lexington International LLC, Transitions Hair Pty Ltd., Cirrus Hair Centers, Vita-Cos-Med Klett-Loch GmbH, Capillus, and Follica, Inc.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Alopecia Market Size And Forecast

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Treatment Market

/in /by

Global Alopecia Treatment Market Research Report 2021-2027

The research team projects that the Alopecia Treatment market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this alopecia report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Teva Pharmaceutical Industries

Merck

Johnson＆Johnson

Reddy`s Laboratories

Cipla

Cellmid

Himalaya Drug

Taisho Pharmaceutical Holdings

By Type

Topical Drugs

Oral Drugs

Injectable

Hair Transplant Services

Other

By Application

Hospitals

Dermatology And Trichology Clinics

Home Care Settings

Other

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

Russia

Spain

Netherlands

Switzerland

Poland

South Asia

India

Pakistan

Bangladesh

South East Asia

Indonesia

Thailand

Singapore

Malaysia

Philippines

Vietnam

Myanmar

Middle East

Turkey

Saudi Arabia

Iran

United Arab Emirates

Israel

Iraq

Qatar

Kuwait

Oman

Africa

Nigeria

South Africa

Egypt

Algeria

Morocoo

Oceania

Australia

New Zealand

South America

Brazil

Argentina

Colombia

Chile

Venezuela

Peru

Puerto Rico

Ecuador

Rest of the World

Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, By Type, By Application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Alopecia Treatment 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend By Types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further, the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Alopecia Treatment Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis By Application Type: Based on the Alopecia Treatment Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

Global Alopecia Treatment Market Research Report 2021-2027

Source

Recent Posts